CMPX Compass Therapeutics (CMPX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001738021
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
151
13F, latest reported quarter
What the filings say about CMPX
Insiders, 180 days
+$21.2K net bought
1 buyer
Compass Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Compass Therapeutics, Inc. insiders bought a net $21.2K of stock across 53 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Sep 24, 2026.
- +45.2% median (+45.2% mean) 90-day return after 2 previous buys.
- The trade is 4.8% of the 420,000 shares held after it.
- No other insider bought within 30 days.
- 151 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lerner Neil bought about $18.4K of CMPX on Oct 1, 2026; 151 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 29, 2026.
- +45.2% median (+45.2% mean) 90-day return after 2 previous buys.
- The trade is 0.6% of the 400,000 shares held after it.
- No other insider bought within 30 days.
- 151 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lerner Neil bought about $2.9K of CMPX on Sep 24, 2026; 151 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 7, 2025.
- The trade is 3.8% of the 397,500 shares held after it.
- 1 other insider bought within 30 days.
- 151 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Lerner Neil bought about $28.4K of CMPX on Apr 29, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days and 151 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 7, 2025.
- The trade is 12.8% of the 196,000 shares held after it.
- 1 other insider bought within 30 days.
- 151 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Anderman Jonathan bought about $47.2K of CMPX on Apr 29, 2026, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days and 151 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 buys), the last on Mar 10, 2023.
- +18.4% median (+29.8% mean) 90-day return after 21 previous buys.
- The trade is 0.2% of the 6,480,825 shares held after it.
- No other insider bought within 30 days.
- 151 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought about $21.1K of CMPX on May 27, 2025; 151 funds added in the latest 13F quarter.53 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$21.2K over 180 days
+$21.2K over 90 days
more than 69% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
151 funds bought in last quarter
more than 82% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
30.5% of the float short (float per yahoo 2026-10-26) · 6.3 days to cover · settled 2026-09-30
more than 96% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 2Chief Accounting Officer Lerner Neil bought $18.4K (Oct 1)
Watch CMPX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-81.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CMPX: institutional holders (13F)
13F holdings, latest reported quarter
17,990,782 sh
$39.4M
15,219,994 sh
$33.3M
14,101,159 sh
$30.9M
11,663,626 sh
$25.5M
11,281,781 sh
$24.7M
Congress trades in CMPX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CMPX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CMPX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$292.4K position · as of 2026-07-31
0.6%
ALPS Medical Breakthroughs ETF
$441.8K position · as of 2026-05-31
0.3%
Meridian Small Cap Growth Fund
$463.8K position · as of 2026-06-30
0.2%
Royce Capital Fund - Micro-Cap Portfolio
$233.7K position · as of 2026-06-30
0.2%
Royce Micro-Cap Fund
$708.3K position · as of 2026-06-30
0.2%
VANGUARD MARKET NEUTRAL FUND
$876.5K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
2 active
2
Phase 2
1 active
1
Multi-phase
1 active
What changed recently
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post
2026-10-10 · Completed → Terminated · The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.
Phase 1
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Ad
2026-09-03 · Completion moved 2026-12-01 → 2027-08-31
PHASE2,PHASE3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $21.2K bought by insiders over 180 days, 151 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CMPX financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM CMPX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM CMPX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$56.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CMPX
| FY Dec 2025 | -$49.2M |
| FY Dec 2024 | -$44.9M |
| FY Dec 2023 | -$40.6M |
| FY Dec 2022 | -$34.3M |
| FY Dec 2021 | -$21.2M |
| Jun 2026 | -$14.9M |
| Mar 2026 | -$17.4M |
| Dec 2025 | -$13.3M |
| Sep 2025 | -$10.9M |
| Jun 2025 | -$11.8M |
| Mar 2025 | -$13.2M |
| Dec 2024 | -$9.2M |
| Sep 2024 | -$11.1M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2021-12-31 (54 months older than the period end) plus current 2021-12-31 (54 months older than the period end); equity 2026-06-30
Debt to equity CMPX
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt CMPX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-56.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CMPX
| FY Dec 2025 | -41.3% |
| FY Dec 2024 | -36.1% |
| FY Dec 2023 | -25.7% |
| FY Dec 2022 | -24.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | -56.7% |
| Mar 2026 | -45.9% |
| Dec 2025 | -41.3% |
| Sep 2025 | -37.8% |
| Jun 2025 | -51.8% |
| Mar 2025 | -41.3% |
| Dec 2024 | -36.1% |
| Sep 2024 | -32.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-47.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CMPX
| FY Dec 2025 | -36.9% |
| FY Dec 2024 | -33.2% |
| FY Dec 2023 | -23.8% |
| FY Dec 2022 | -22.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | -47.9% |
| Mar 2026 | -40.5% |
| Dec 2025 | -36.9% |
| Sep 2025 | -34.6% |
| Jun 2025 | -45.6% |
| Mar 2025 | -37.7% |
| Dec 2024 | -33.2% |
| Sep 2024 | -29.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CMPX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-58.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CMPX
| FY Dec 2025 | -43.2% |
| FY Dec 2024 | -40.4% |
| FY Dec 2023 | -30.3% |
| FY Dec 2022 | -25.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | -58.6% |
| Mar 2026 | -48.3% |
| Dec 2025 | -43.2% |
| Sep 2025 | -39.3% |
| Jun 2025 | -54.5% |
| Mar 2025 | -45.2% |
| Dec 2024 | -40.4% |
| Sep 2024 | -36.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing CMPX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$101.6M
market value at close 2026-10-23 on 2026-07-28 shares, plus long-term 2021-12-31 (54 months older than the period end) plus current 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
Enterprise value CMPX
| FY Dec 2025 | $924.5M |
| FY Dec 2024 | $156.0M |
| FY Dec 2023 | $174.7M |
| FY Dec 2022 | $599.8M |
| FY Dec 2021 | $166.2M |
| Jun 2026 | $358.9M |
| Mar 2026 | $897.5M |
| Dec 2025 | $924.5M |
| Sep 2025 | $437.8M |
| Jun 2025 | $336.7M |
| Mar 2025 | $221.7M |
| Dec 2024 | $156.0M |
| Sep 2024 | $233.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-41.1%
TTM free cash flow over market value at close 2026-10-23
FCF yield CMPX
| FY Dec 2025 | -5.1% |
| FY Dec 2024 | -22.5% |
| FY Dec 2023 | -20.4% |
| FY Dec 2022 | -5.4% |
| FY Dec 2021 | -6.8% |
| Jun 2026 | -14.3% |
| Mar 2026 | -5.6% |
| Dec 2025 | -5.1% |
| Sep 2025 | -9.3% |
| Jun 2025 | -12.6% |
| Mar 2025 | -16.8% |
| Dec 2024 | -22.5% |
| Sep 2024 | -19.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing CMPX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $850.0K | $0 | n/a |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M |
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M |
| Cash | $30.6M | $43.5M | $24.2M | $34.9M |
SEC XBRL, fiscal years, as known on 2026-10-27
CMPX Stock Sonar score 6/7 axes
Find similar shapesCompareCMPX ranks highest on financial health (99th percentile) and institutional and government (82nd), and lowest on growth (1st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CMPX filings, in plain words
Are Compass Therapeutics insiders buying or selling CMPX?
In the 180 days to 2026-10-27, Compass Therapeutics insiders were net buyers, a net $21.2K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-27, Compass Therapeutics insiders were net buyers of CMPX, a net $21.2K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
